JP2023503465A5 - - Google Patents
Info
- Publication number
- JP2023503465A5 JP2023503465A5 JP2022530662A JP2022530662A JP2023503465A5 JP 2023503465 A5 JP2023503465 A5 JP 2023503465A5 JP 2022530662 A JP2022530662 A JP 2022530662A JP 2022530662 A JP2022530662 A JP 2022530662A JP 2023503465 A5 JP2023503465 A5 JP 2023503465A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- cycloalkyl
- group
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19383037.9 | 2019-11-25 | ||
| EP19383037 | 2019-11-25 | ||
| PCT/IB2020/061158 WO2021105908A1 (en) | 2019-11-25 | 2020-11-25 | Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503465A JP2023503465A (ja) | 2023-01-30 |
| JP2023503465A5 true JP2023503465A5 (https=) | 2023-11-17 |
| JP7691753B2 JP7691753B2 (ja) | 2025-06-12 |
Family
ID=68808239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530662A Active JP7691753B2 (ja) | 2019-11-25 | 2020-11-25 | ベータ－グルコセレブロシダーゼの活性の変質に関連する状態におけるヘテロアリール化合物およびその治療的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230107499A1 (https=) |
| EP (1) | EP4065563A1 (https=) |
| JP (1) | JP7691753B2 (https=) |
| KR (1) | KR20220150878A (https=) |
| CN (1) | CN115348959B (https=) |
| AU (1) | AU2020394602A1 (https=) |
| BR (1) | BR112022010126A2 (https=) |
| IL (1) | IL293309A (https=) |
| MX (1) | MX2022006065A (https=) |
| WO (1) | WO2021105908A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4642455A1 (en) | 2022-12-30 | 2025-11-05 | GT Gain Therapeutics SA | Method of treating tauopathies |
| WO2025221055A1 (ko) * | 2024-04-18 | 2025-10-23 | 에스케이바이오팜 주식회사 | 유레아 화합물 및 이의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1052988A (https=) * | 1962-07-03 | |||
| ES2273047T3 (es) * | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
| SI2995306T1 (sl) | 2009-10-19 | 2019-04-30 | Amicus Therapeutics, Inc. | Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja |
| KR101987736B1 (ko) | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| MA42189A (fr) * | 2015-04-15 | 2018-04-18 | Biomarin Pharm Inc | Mã‰thodes de traitement des troubles du stockage lysosomal |
| CN110325516A (zh) * | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | 杂芳基化合物和它们的用途 |
-
2020
- 2020-11-25 AU AU2020394602A patent/AU2020394602A1/en active Pending
- 2020-11-25 JP JP2022530662A patent/JP7691753B2/ja active Active
- 2020-11-25 KR KR1020227020878A patent/KR20220150878A/ko active Pending
- 2020-11-25 EP EP20815952.5A patent/EP4065563A1/en active Pending
- 2020-11-25 WO PCT/IB2020/061158 patent/WO2021105908A1/en not_active Ceased
- 2020-11-25 CN CN202080089317.0A patent/CN115348959B/zh active Active
- 2020-11-25 US US17/779,482 patent/US20230107499A1/en active Pending
- 2020-11-25 BR BR112022010126A patent/BR112022010126A2/pt unknown
- 2020-11-25 IL IL293309A patent/IL293309A/en unknown
- 2020-11-25 MX MX2022006065A patent/MX2022006065A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2447253B1 (en) | Dihydropyrimidine compounds, preparation methods, pharmaceutical compositions thereof and their use as antiviral agents | |
| JP2020519606A5 (https=) | ||
| CN102112453A (zh) | 新的钾通道阻断剂及其用途 | |
| IL322686A (en) | Heterocyclic glp-1 agonists | |
| JP2017525737A (ja) | キノリノン系化合物及びその薬物への使用 | |
| US10479790B2 (en) | COMT inhibiting methods and compositions | |
| JP2020504122A5 (https=) | ||
| JP2023503465A5 (https=) | ||
| JP2019501919A (ja) | スルファミド誘導体およびその製造方法と応用 | |
| KR20150103034A (ko) | 피리돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도 | |
| JP4285723B2 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| JP2021509907A (ja) | アセタール化合物およびその治療的使用 | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| US20170197981A1 (en) | Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria | |
| JP6310923B2 (ja) | ジヒドロピリミジン誘導体の結晶形 | |
| TNSN05080A1 (en) | NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published) | |
| JP2022519764A (ja) | 二環式スルホンアミド | |
| CA2398186A1 (en) | Therapeutic agent for reperfusion injury comprising integrin .alpha.v.beta.3 antagonists | |
| US9126989B2 (en) | Compound and methods for treating long QT syndrome | |
| US20230019280A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| JP2013542976A (ja) | ニトロベンゾチアゾール誘導体および結核治療のためのこれらの使用 | |
| JP2023503470A5 (https=) | ||
| JP2020514284A5 (https=) | ||
| CS277691A3 (en) | 3-/1h-indazol-3-yl/-4-pyridinamines, process and intermediates for their preparation and their application as medicaments | |
| AU2020286962B2 (en) | Heterocyclic immunomodulators as PDL1 checkpoint inhibitor |